A Phase IIB, Randomized, Double-Blinded, Placebo-Controlled Study of Low Dose Cytarabine and Lintuzumab Compared to Low Dose Cytarabine and Placebo in Patients 60 Years of Age and Older With Previously Untreated AML
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Overall survival
12 months
No
Eric Sievers, MD
Study Director
Seattle Genetics, Inc.
United States: Food and Drug Administration
SG033-0003
NCT00528333
September 2007
August 2010
Name | Location |
---|---|
Memorial Sloan Kettering Cancer Center | New York, New York 10021 |
Cleveland Clinic Foundation | Cleveland, Ohio 44195 |
University of Colorado Cancer Center | Denver, Colorado 80262 |
Rush University Medical Center | Chicago, Illinois 60612-3824 |
Cancer Centers of the Carolinas | Greenville, South Carolina 29605 |
Western Pennsylvania Cancer Institute | Pittsburgh, Pennsylvania 15224 |
University of California Los Angeles | Los Angeles, California 90095-6951 |
Tower Cancer Research Foundation | Beverly Hills, California 90211 |
Kenmar Research Institute | Los Angeles, California 90057 |
Lakeland Regional Cancer Center | Lakeland, Florida 33805 |
H. Lee Moffitt Cancer Center & Research Institute | Tampa, Florida 33612 |
Glendale Memorial Hospital | Glendale, California 91204 |
Bay Area Cancer Research Group | Concord, California 94520 |
University of Texas, MD Anderson Cancer Center | Houston, Texas 77030 |
Gunderson Clinic | LaCrosse, Wisconsin 54601 |
Southern Cancer Center | Mobile, Alabama 36608 |
Joliet Oncology-Hematology Associates | Joliet, Illinois 60435 |
Michigan State University, Breslin Cancer Center | Lansing, Michigan 48910 |
Billings Clinic Cancer Research | Billings, Montana 59101 |
Northshore University Hospital, Monter Cancer Center | Lake Success, New York 11042 |